|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
KR101589785B1
(ko)
|
2009-03-10 |
2016-01-28 |
바이오젠 엠에이 인코포레이티드 |
항-ｂｃｍａ 항체
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
ES3065694T3
(en)
|
2012-04-11 |
2026-05-07 |
Us Health |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
US20130280220A1
(en)
|
2012-04-20 |
2013-10-24 |
Nabil Ahmed |
Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
|
|
SI3300745T1
(sl)
*
|
2013-02-15 |
2020-01-31 |
The Regents Of The University Of California |
Himerni antigenski receptor in postopki njihove uporabe
|
|
MX357011B
(es)
|
2013-03-15 |
2018-06-22 |
Amgen Inc |
Anticuerpos biespecificos heterodimericos.
|
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CA2931641C
(en)
|
2013-12-30 |
2022-05-10 |
Epimab Biotherapeutics Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
US20160333108A1
(en)
*
|
2014-01-13 |
2016-11-17 |
Stephen J. Forman |
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
|
|
CN106536564B
(zh)
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
KR20180077193A
(ko)
|
2015-10-30 |
2018-07-06 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
예후 방법
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
SG11201900344YA
(en)
*
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
KR102512934B1
(ko)
|
2016-08-10 |
2023-03-23 |
레전드 바이오테크 아일랜드 리미티드 |
Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
|
|
MA46236A
(fr)
|
2016-09-14 |
2019-07-24 |
Janssen Biotech Inc |
Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
|
|
US20190119636A1
(en)
|
2017-10-23 |
2019-04-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
AU2017357649A1
(en)
|
2016-11-11 |
2019-05-23 |
Autolus Limited |
Chimeric antigen receptor
|
|
US11440958B2
(en)
|
2016-11-22 |
2022-09-13 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
|
MA46998A
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
|
CN108395478A
(zh)
*
|
2017-02-04 |
2018-08-14 |
上海恒润达生生物科技有限公司 |
靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
|
|
CA3053640A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Unum Therapeutics Inc. |
Co-use of anti-bcma antibody and antibody-coupled t celll receptor (actr) in cancer therapy and b cell disorders
|
|
CA3062433A1
(en)
*
|
2017-05-15 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
CN109593721B
(zh)
*
|
2017-09-30 |
2022-11-01 |
亘喜生物科技（上海）有限公司 |
具有自杀基因开关的靶向人间皮素的工程化免疫细胞
|
|
US11905528B2
(en)
*
|
2017-10-12 |
2024-02-20 |
Icell Gene Therapeutics Inc. |
Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
|
|
IL279063B2
(en)
|
2018-05-31 |
2026-05-01 |
Washington Univ |
Chimeric antigen receptor T cells for cancer treatment
|
|
SG11202101204TA
(en)
|
2018-08-09 |
2021-03-30 |
Juno Therapeutics Inc |
Processes for generating engineered cells and compositions thereof
|
|
PT3844267T
(pt)
|
2018-08-31 |
2025-09-30 |
Novartis Ag |
Métodos de preparação de células que expressam recetor de antigénio quimérico
|
|
WO2020088631A1
(en)
|
2018-11-01 |
2020-05-07 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
CN109468283A
(zh)
*
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN109485734B
(zh)
*
|
2018-12-30 |
2020-05-12 |
广州百暨基因科技有限公司 |
一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3964238A4
(en)
*
|
2019-05-07 |
2022-09-14 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
MANIPULATED IMMUNE CELL TARGETING BCMA AND USE THEREOF
|
|
DK3967329T3
(da)
*
|
2019-05-07 |
2026-05-11 |
Gracell Bioscience Shanghai Co Ltd |
Genmanipuleret immuncelle, der er målrettet mod bcma, og anvendelse deraf
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
CN115777017A
(zh)
*
|
2020-05-06 |
2023-03-10 |
亘喜生物科技（上海）有限公司 |
用于t细胞工程改造的组合物及方法
|
|
WO2025031469A1
(en)
*
|
2023-08-10 |
2025-02-13 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Use of dual-target car-t cells in treating b-cell autoimmune diseases
|